NASDAQ · CTSO
Cytosorbents Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CTSO: Nov 12, 2026
Cytosorbents Corporation Common Stock is expected to report earnings on 11/12/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.9. The reported EPS for the same quarter last year was $-0.8.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.90 | $-0.80 | $-1.00 | 2 |
| Dec 2026 | $-0.70 | $-0.60 | $-0.80 | 2 |
| Mar 2027 | $0.00 | $0.00 | $0.00 | 1 |
| Jun 2027 | $0.00 | $0.00 | $0.00 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · Quiver Quantitative- Fintel · Sep 14, 10:25 PM EDTCytosorbents Consensus Price Target Increased by 1,900% to $48.45The average one-year price target for Cytosorbents (NASDAQCM:CTSO) has been revised to $48.45 / share. This is an increase of 1,900.00% from the prior estimate of $2.42 dated August 25, 2026. These figures represent aggregate analyst targets collected by Fintel and do not consti
- RTTNews · Sep 3, 7:25 AM EDTCytosorbents To Implement 1-For-20 Reverse Stock Split, Stock Down In Pre-Market(RTTNews) – Thursday, Cytosorbents Corporation (CTSO) announced its plan to implement a one-for-twenty reverse stock split of its common stock, par value $0.001 per share, effective September 8, 2026.
- RTTNews · Sep 2, 8:26 AM EDTCytosorbents Real-World Data Shows CytoSorb Reduces Severe Bleeding In Cardiac Surgery(RTTNews) – Wednesday, Cytosorbents Corp. (CTSO) announced an independent new patient-level matched analysis of the company's flagship product CytoSorb.
- The Motley Fool · Aug 13, 7:29 PM EDTCytosorbents (CTSO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · Jun 2, 12:36 PM EDTCytosorbents (CTSO) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · Mar 26, 10:40 AM EDTCytosorbents (CTSO) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Dec 16, 7:06 PM ESTD. Boral Capital Maintains Cytosorbents (CTSO) Buy RecommendationFintel reports that on December 16, 2025, D. Boral Capital maintained coverage of Cytosorbents (NasdaqCM:CTSO) with a Buy recommendation. Analyst Price Forecast Suggests 736.72% Upside
- Fintel · Nov 14, 7:07 PM ESTHC Wainwright & Co. Maintains Cytosorbents (CTSO) Neutral RecommendationFintel reports that on November 14, 2025, HC Wainwright & Co. maintained coverage of Cytosorbents (NasdaqCM:CTSO) with a Neutral recommendation. Analyst Price Forecast Suggests 672.73% Upside
- The Motley Fool · Nov 13, 5:14 PM ESTCytosorbents (CTSO) Q3 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Sep 16, 7:32 AM EDTCytoSorbents Issues Regulatory Update On DrugSorb-ATR; Plans To File New De Novo Application(RTTNews) – CytoSorbents (CTSO) issued a regulatory update on DrugSorb-ATR. The company has decided to not file a final appeal with CDRH because of positive FDA upper management feedback for a reasonable path forward that would allow for a suitable and potentially expedited De No
- Quiver Quantitative · Jul 21, 2:20 PM EDTNew Analyst Forecast: $CTSO Given $10.0 Price TargetWe just received data on a new analyst forecast for $CTSO. Jason Kolbert from D. Boral Capital set a price target of 10.0 for CTSO.
- RTTNews · Jul 2, 7:25 AM EDTCytoSorbents Issues Regulatory Update For DrugSorb-ATR(RTTNews) – CytoSorbents (CTSO) issued a regulatory update on its marketing applications for DrugSorb-ATR with the FDA and Health Canada. On June 27, 2025, the FDA confirmed the scheduling of an appeal hearing date for the company's requested supervisory review. The company conti
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cytosorbents Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.